secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0000950170-24-125921
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharma Q3 net loss $19.1M; neffy launch progressing; ALK deal $145M
-----------------------------------------------------------------------

- Net loss of $19.1M for Q3 2024; total revenue of $2.1M including $0.6M neffy product revenue from one week of sales.
- Cash, equivalents & short-term investments $204.6M at Sept 30; pro forma $349.6M after $145M upfront from ALK-Abelló deal.
- FDA granted priority review for neffy 1mg sNDA; PDUFA date March 6, 2025 for children weighing 15-30 kg.
- Exclusive license with ALK-Abelló for neffy in Europe, Canada, etc.; total consideration up to $465M plus double-digit royalties.
- Over 5,700 HCPs reached, 1,700+ prescriptions submitted, and 1,000 allergists enrolled in neffy Experience Program since launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000095017024125921/0000950170-24-125921-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000095017024125921/spry-20241113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-125921

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer